Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

The price of empagliflozin, a commonly prescribed diabetes drug, has been slashed by a staggering 90% in India. This ...

Glenmark Pharmaceuticals launches Empagliflozin, an SGLT2 inhibitor, in India under the brand name Glempa for glycemic ...

Glenmark launches Empagliflozin and combinations in India under Glempa brand, aiming to improve glycemic control and reduce ...

Mankind Pharma has launched generic versions of diabetes medication Empagliflozin under brand names Empaglyde, Empagreat, and ...

Prices of key anti-diabetic drug empagliflozin crashed by as much as 90 per cent to ₹5.5 per tablet as several pharma ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...

Indian drug companies are set to revolutionize diabetes treatment with affordable generic versions of Empagliflozin, ...